Richard Nowak, MD, MS
Assistant Professor of Neurology; Director, Program in Clinical & Translational Neuromuscular Research; Director, Yale Myasthenia Gravis Clinic
Research & Publications
Biography
News
Locations
Research Summary
Dr. Nowak is focused on elucidating the immunopathologic mechanisms of myasthenia gravis, an autoimmune disorder targeting the neuromuscular junction in patients resulting in weakness. He is working toward identifying new drug targets as well as exploring the effectiveness of B cell directed therapies (e.g., rituximab).
Specialized Terms: Myasthenia Gravis; Guillian-Barre Syndrome (GBS); CIDP; Immune Therapies, Neuropathy; Charcot Marie Tooth Disease; ALS.
Extensive Research Description
https://medicine.yale.edu/neurology/divisions/neuromuscular/nmresearch.aspx
Coauthors
Research Interests
Amyotrophic Lateral Sclerosis; Charcot-Marie-Tooth Disease; Myasthenia Gravis; Neurology; Guillain-Barre Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Selected Publications
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances In Neurological Disorders 2011, 4: 259-66. PMID: 22010039, PMCID: PMC3187675, DOI: 10.1177/1756285611411503.
- Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. Journal Of Medicinal Chemistry 2010, 53: 2709-18. PMID: 20232802, PMCID: PMC2881568, DOI: 10.1021/jm901062p.
- Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation.Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 3639-44. PMID: 15738401, PMCID: PMC553303, DOI: 10.1073/pnas.0408277102.
- An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis.Ray SS, Nowak RJ, Strokovich K, Brown RH, Walz T, Lansbury PT. An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry 2004, 43: 4899-905. PMID: 15109247, DOI: 10.1021/bi030246r.
- Self-assembly of Abeta(1-42) into globular neurotoxins.Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42: 12749-60. PMID: 14596589, DOI: 10.1021/bi030029q.
- Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. Journal Of Molecular Biology 2002, 322: 1089-102. PMID: 12367530, DOI: 10.1016/s0022-2836(02)00735-0.
- Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes.Anguiano M, Nowak RJ, Lansbury PT. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41: 11338-43. PMID: 12234175, DOI: 10.1021/bi020314u.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Nervous System | Myasthenia Gravis Inebilizumab Trial (MINT) |
Diseases of the Musculoskeletal System | Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT) |
Diseases of the Nervous System | Immunologic Mechanisms in Neurological Diseases |